Bioavailability profile of Uceris MMX extended-release tablets compared with Entocort EC capsules in healthy volunteers

@article{Nicholls2013BioavailabilityPO,
  title={Bioavailability profile of Uceris MMX extended-release tablets compared with Entocort EC capsules in healthy volunteers},
  author={A. Nicholls and Ra{\'u}l Harris-Collazo and Michael Huang and Yun J Hardiman and Richard J. Jones and L. Moro},
  journal={Journal of International Medical Research},
  year={2013},
  volume={41},
  pages={386 - 394}
}
Objective To compare the pharmacokinetics of the extended-release MMX® formulation of budesonide (Uceris®) with that of Entocort® EC, an extended (controlled ileal) release formulation of budesonide. Methods Using an open-label, randomized, three-period crossover, Latin square design, healthy male or female volunteers received single doses of 6 mg Uceris®, 9 mg Uceris® or 9 mg Entocort® EC. Standard pharmacokinetic parameters were assessed. Results The study included 12 subjects. The 9 mg… Expand
19 Citations

Paper Mentions

Novel extended release budesonide formulation for treatment of ulcerative colitis
Budesonide MMX®: A Review of Its Use in Patients with Mild to Moderate Ulcerative Colitis
Budesonide for the treatment of ulcerative colitis
Predicting budesonide performance in healthy subjects and patients with Crohn's disease using biorelevant in vitro dissolution testing and PBPK modeling.
Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis
...
1
2
...

References

SHOWING 1-10 OF 19 REFERENCES
Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation.
Rectal pharmacokinetics of budesonide.
Budesonide (Entocort® EC Capsules)
[Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations].
Budesonide versus prednisolone retention enemas in active distal ulcerative colitis
...
1
2
...